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Preface
Tuberculosis (TB) is a leading chronic bacte-
rial infection. Despite potentially curative phar-
macotherapies being available for over 50 years, 
the length of the treatment and the pill burden 
can hamper patient lifestyle. Prolonged treat-
ment, high pill burden, low compliance, and 
stiff administration schedules are factors that 
are responsible for the emergence of multidrug-
resistant strains. According to WHO reports, 
53 million TB patients died from 2000 to 2016. 
Therefore, early diagnosis of the disease is of 
great importance for global health care pro-
grams. Various unique antibodies have been 
developed to overcome drug resistance, reduce 
the treatment regimen, and elevate the compli-
ance to treatment. Therefore, we need an effec-
tive and robust system to subdue technological 
drawbacks and improve the effectiveness of 
therapeutic drugs which remains a major chal-
lenge for pharmaceutical technology.
Regarding TB treatment, nanoparticles can be 
a useful strategy for two distinct applications: 
(1) for their intrinsic antimycobacterial activ-
ity and (2) as vehicles for known antitubercular 
drugs to allow the reduction of dose- and drug-
associated side-effects and administration via 
user-friendly administration routes such as pul-
monary or oral ones.
This book will summarize the types of nano-
drugs, their synthesis, formulation, characteriza-
tion, and applications, with the most important 
administration routes. Thus, this book will dis-
cuss various nanotechnology-based approaches 
which may help overcome persisting limitations 
of conventional/traditional treatment. Also, re-
cent advances and achievements regarding ther-
apeutic efficacy provide possible future applica-
tions in this field. In this scenario, this book will 
directly address all translational aspects and 
clinical perspectives of TB nanomedicine from 
a comprehensive and multidisciplinary percep-
tion. This book is thus (1) an unrivalled, compre-
hensive summary of the field and (2) rationally 
conceived clinical stage of TB nanomedicines. 
The editor and contributors (authors) cover a 
wide range of expertise in the nanomedicine 
and TB and all of them are already proven their 
international acclaim.
We thank all the authors for their valuable 
and timely contributions. We believe that the 
book, with its comprehensive coverage of fun-
damental and applied aspects of the subject, 
will prove immensely useful to its readers and 
stimulate further interest.
Prashant Kesharwani
C H A P T E R
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Abbreviations
AFB Acid Fast Basil
MDR-TB multidrug resistant tuberculosis
M.tb Mycobacterium tuberculosis
TB tuberculosis
XDR-TB extra-drug resistant tuberculosis
RIF rifampicin
INH isoniazid
PYR pyrazinamide
ETB ethambutol
1 Mycobacterium: pathogenesis and its 
problem in the resistant
Tuberculosis (TB) is an air-borne chronic in-
fection caused by Mycobacterium tuberculosis 
(M.tb). It has a high affinity to the parenchymal 
tissue of lungs due to the high oxygen level. My-
cobacterium tuberculosis (M.tb) is a Gram-positive 
acid-resistant stem and called Acid Fast Basils 
(AFB). The golden standard in identified TB in-
fection is the count of AFB smears from sputum, 
for TB in the lung or other specimens, for extra-
pulmonary TB [1].
Pathogen M.tb is easily to die with direct sun-
light. However, it survives in dark and damp 
places, even it is outside the host. Mycobacterium 
tuberculosis transmits through aerosol droplets 
from coughing, sneezing, or saliva splashes of 
people infected TB lungs. The droplet diameter 
is very small (0.5-5 µm) and around 40,000 bac-
teria are produced each sneezing, therefore M.tb 
eases to transmitted [1].
After the inhalation of M. tuberculosis, innate 
immune responses involving alveolar macro-
phages and granulocytes begin to combat the in-
fection; in some persons, the bacilli are cleared, 
whereas in others, infection is established [2]. 
The replication of bacilli in macrophages and re-
gional lymph nodes leads to both lymphatic and 
hematogenous dissemination, with seeding of 
multiple organs, which may eventually give rise 
to extrapulmonary disease. The containment of 
bacilli within macrophages and extracellularly 
within granulomas limits further replication 
and controls tissue destruction, resulting in a 
dynamic balance between pathogen and host. 
The classic interpretation of this as a binary 
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process with either truly latent M. tuberculosis 
infection or active tuberculosis disease has re-
cently been challenged as an oversimplification. 
Instead, a spectrum of immunologic responses 
that are both protective and pathogenic and cor-
relate with a range of bacterial activation has 
been suggested. This continuum encompasses a 
variety of host-microbe interactions, which are 
characterized by clinical latency when host re-
sponses predominate and by disease when bac-
terial replication exceeds the threshold required 
to cause symptoms [2-4]. Recent evidence sug-
gests that host inflammatory responses, particu-
larly with interleukin-1β, may actually enhance 
mycobacterial replication, which illustrates that 
the double-edged sword of immune responses 
seen in tuberculosis disease may also be present 
in latent infection (as shown in Fig. 15.1).
Mycobacterium tuberculosis forms into an ac-
tive, clinically silent, and latent infection. It said 
that one-third of the world’s population infected 
by M.tb, most of them are asymptomatic and be-
come latent tuberculosis infection especially in 
people with immunocompromised conditions, 
for example, HIV/AIDS, DM, malnutrition, on 
chemotherapy or steroids therapy, and antitu-
mor therapy necrosis factor. Only about 5%-10% 
suffer from active tuberculosis infection [1].
Tuberculosis (TB), the infection caused by My-
cobacterium tuberculosis (M.tb), remains a problem 
to overcome in Indonesia. In East Java Provence 
Indonesia 2018, the incidence of new TB cases 
reached 767 from 100,000 population [6]. This 
phenomenon was similar to TB incidence in the 
world. According to the World Health Organiza-
tion (WHO) data in 2013, it states that the inci-
dence of new TB cases in the world has increased 
50%, and therefore WHO has declared for TB as 
a “global health emergency” [7]. The pathology 
mechanism of TB could be seen in Fig. 15.2.
Mycobacteria, especially Mycobacterium tubercu-
losis (M.tb), are intrinsically resistant to most anti-
biotics [9]. They have the ability in growing slower 
than other bacteria. There is no single antibiotic 
that is relatively effective against M.tb, therefore 
for tuberculosis (TB) multidrugs therapy (MDT) 
is required to avoid bacterial resistant [9,10]. My-
cobacterial cells are lipid-rich and also able to be 
dormant that causes impermeable and poorly pen-
etrate for many agents, including macrophages. 
FIGURE 15.1 The main subcellular events of M. tuberculosis infection in macrophage [5].
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Finally, M. tuberculosis has the ability to manipulate 
both innate and adaptive immune response and 
called TB’s escape mechanism. In this mechanism, 
M.tb has a high ability to avoid intracellular kill-
ing process and macrophage phagocytosis process 
[11,12]. Mycobacteria are notorious for their ability 
to develop resistance [9,10]. Moreover, phagosome 
maturation, which is activated during M.tb recog-
nition process, is the decrease of intra-vacuole pH, 
from ∼7 to 5. This acidification represents a fun-
damental blocking step in the process of bacterial 
elimination [5].
The worldwide emergence and spread of 
drug-resistant M. tuberculosis strains is a serious 
concern considering the high death rate associat-
ed with such infections. To tackle this issue, new 
therapeutic molecules and vaccination/preven-
tion strategies have to be developed. However, 
such developments may require a better under-
standing of how M. tuberculosis blocks the innate 
defenses of the host to establish its intra-cellular 
replicative niche [5].
2 Antituberculosis and the mechanism of 
antituberculosis resistant
The aims of antituberculosis (anti-TB) are 
(1) to cure the patient; (2) to prevent death; (3) 
to prevent recurrence; (4) to break the chain of 
transmission; and (5) to prevent M.tb resistant. 
Mycobacterium has ability to grow very slowly 
and develop resistance rapidly. Therefore, to treat 
TB, several combinations or TB-MDT are needed.
Tuberculosis MDT is classified into two lines: 
the first line of TB MDT is rifampicin (RIF), 
FIGURE 15.2 Pathology of tuberculosis [8].
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isoniazid (INH), pyrazinamide (PYR), ethambu-
tol (ETB), and streptomycin. This group of drugs 
exhibits high effectiveness with acceptable toxic-
ity [9,10,13]. The second line of TB-MDT is the 
antibiotics fluro-quinolones (such as ciprofloxa-
sin, ofloxasin, levofloxasin, mofifloxacin), mac-
rolides (such as erythromycin, clarithromycin), 
and aminoglycosides (such as amikacin, kana-
mycin, and capreomycin) [9,10,13].
The aims of TB-MDT are (1) to increase bac-
tericidal activity, starting from the beginning of 
therapy phase; (2) to prevent drug resistant; and 
(3) to enhance the process of eliminating M. tu-
berculosis in the sites of TB infection [9,10,13].
Isoniazid is the primary drug for chemothera-
py of TB infection with the highest bactericidal 
activity at the beginning of TB treatment. All pa-
tients infected with isoniazid-sensitive strains of 
the tubercle bacillus should receive the drug if 
they can tolerate it. The use of combination ther-
apy (isoniazid + pyrazinamide + rifampin) pro-
vides the basis for “short-course” therapy and 
improved remission rates [9,10]. The mechanism 
of action of anti-TB could be seen in Fig. 15.3.
FIGURE 15.3 Mechanism of pharmacotherapy in tuberculosis [8].
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The isoniazid’s efficacy gets higher when it 
combined with ethambutol, rifampicin, pyra-
zinamide, and streptomycin. Rifampicin has 
the highest elimination ability of M. tuberculosis. 
Isoniazid enters bacilli by passive diffusion. The 
drug is not directly toxic to the bacillus but must 
be activated to its toxic form within the bacillus 
by KatG, a multifunctional catalase-peroxidase. 
KatG catalyzes the production from isoniazid 
of an isonicotinoyl radical that subsequently 
interacts with mycobacterial NAD and NAPD 
to produce a dozen adducts. One of these, a 
nicotinoyl-NAD isomer, inhibits the activities of 
enoyl acyl carrier protein reductase (InhA) and 
-ketoacyl acyl carrier protein synthase (KasA). 
Inhibition of these enzymes inhibits synthesis 
of mycolic acid, an essential component of the 
mycobacterial cell wall, leading to bacterial cell 
death. The products of KatG activation of INH 
include superoxide, H2O2, alkyl hydroperox-
ides, and the NO radical, which may also con-
tribute to the mycobactericidal effects of INH. 
M. tuberculosis could be especially sensitive to 
damage from these radicals because the bacil-
li have a defect in the central regulator of the 
oxidative stress response, oxyR. Backup defense 
against radicals is provided by alkyl hydroper-
oxide reductase (encoded by ahpC), which de-
toxifies organic peroxides. Increased expression 
of ahpC reduces isoniazid effectiveness [10]. The 
antibacterial effect of isoniazid against clini-
cal M.tb strains varies between 0.025 and 0.05 
mg/L. Activity against Mycobacterium bovis and 
M. kansasii is moderate. Isoniazid has poor ac-
tivity against MAC. It has no activity against 
any other microbial genus [10]. The prevalence 
of drug-resistant mutants is ∼1 in 106 bacilli. 
TB cavities may contain as many as 107 to 109 
microorganisms; preexistence resistance can be 
expected in pulmonary TB cavities of untreated 
patients. These spontaneous mutants can be 
selected by monotherapy; indeed, strains resis-
tant to isoniazid will be selected and amplified 
by isoniazid monotherapy. Thus two or more 
agents are usually used. The mutations result-
ing in drug resistance are independent events, 
the probability of resistance to two antimyco-
bacterial agents is small, ∼1 in 1012 (1 × 106 × 
106), a low probability considering the number 
of bacilli involved. Resistance to INH is associ-
ated with mutation or deletion of katG, overex-
pression of the genes for inhA (confers low-level 
resistance to INH and some cross-resistance to 
ethionamide), and ahpC and mutations in the 
kasA and katG genes. KatG mutants exhibit a 
high level of resistance to isoniazid (as shown 
in Fig. 15.4).
Rifampicin inhibits the growth of most Gram-
positive bacteria as well as many Gram-nega-
tive microorganisms such as Escherichia coli, 
Pseudomonas, indole-positive and indole-nega-
tive Proteus, and Klebsiella. Rifampicin is very 
active against Staphylococcus aureus and coag-
ulase-negative staphylococci. The drug also is 
highly active against Neisseria meningitidis and 
Haemophilus influenzae. Rifampicin inhibits the 
growth of many M. tuberculosis clinical isolates 
in vitro at concentrations of 0.06-0.25 mg/L 
[10]. The prevalence of rifampicin-resistant iso-
lates is 1 in every 107 to 108 bacilli. Microbial 
resistance to rifampin is due to an alteration 
of the target of this drug, rpoB, with resistance 
in 86% of cases due to mutations at codons 526 
and 531 of the rpoB gene [10].Pyrazinamide is 
the synthetic pyrazine analog of nicotinamide. 
Pyrazinamide is also known as pyrazinoic acid 
amide, pyrazine carboxylamide, and pyrazin-
ecarboxamide. Pyrazinamide is “activated” by 
acidic conditions. Initially it was assumed that 
the acidic conditions under which pyrazin-
amide works were inside macrophage phago-
somes. However, pyrazinamide may not be very 
effective within macrophages; rather, the acidic 
conditions for activation may be at the edges of 
necrotic TB cavities where inflammatory cells 
produce lactic acid. M. tuberculosis nicotinami-
dase or pyrazinaminidase deaminates pyrazin-
amide to pyrazinoic acid (POĀ), which is then 
transported to the extracellular milieu by an ef-
flux pump. In an acidic extracellular milieu, a 
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fraction of POĀ is protonated to POAH, a more 
lipid-soluble form that enters the bacillus. The 
actual mechanism of pyrazinamide microbial 
kill is still unclear; three mechanisms have been 
proposed [10]:
1. inhibition of fatty acid synthase type I 
leading to interference with mycolic acid 
synthesis,
2. reduction of intracellular pH, and
3. disruption of membrane transport by HPOA.
Antibacterial activity of pyrazinamide in vi-
tro only at acidic pH. At pH of 5.8-5.95, 80%-90% 
of clinical isolates have a MIC of 100 mg/L. Pyr-
azinamide-resistant occurs when M.tb has pyra-
zinamidase to reduce affinity for pyrazinamide. 
This reduced affinity decreases the conversion 
of pyrazinamide to POA. Single point mutations 
in the pncA gene are encountered in up to 70% 
of resistant clinical isolates. The mechanisms 
contributing to resistance in 30% of resistant 
clinical isolates is unclear [10].
Ethambutol inhibits arabinosyl transferase III, 
thereby disrupting the transfer of arabinose into 
arabinogalactan biosynthesis, which in turn dis-
rupts the assembly of mycobacterial cell wall. 
The arabinosyl transferases are encoded by 
embAB genes. Ethambutol has activity against 
a wide range of mycobacteria but no activity 
against any other genus. Ethambutol MICs are 
0.5-2 mg/L in clinical isolates of M.tb [10]. In vi-
tro, mycobacterial resistance to the drug devel-
ops via mutations in the embB gene. In 30%-70% 
of clinical isolates that are resistant to etham-
butol, mutations are encountered at codon 306 
of the embB gene. However, mutations in this 
codon are also encountered in ethambutol-sus-
ceptible mycobacteria, as though this mutation 
is necessary, but not sufficient, to confer etham-
butol resistance [10].
FIGURE 15.4 Mechanism of action of isoniazid [10].
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A combination of isoniazid-rifampicin for 
9 months administration will cure 95%-98% of 
cases of tuberculosis infection caused by sus-
ceptible strains [9]. An initial intensive phase of 
treatment is recommended for the first 2 months 
due to the prevalence of resistant strains. The 
addition of pyrazinamide during this intensive 
phase allows the total duration of therapy to be 
reduced to 6 months without the loss of effica-
cy. In practice, therapy is usually initiated with 
a four-drug regimen of isoniazid, rifampicin, 
pyrazinamide, and ethambutol until suscepti-
bility of the clinical isolate has been determined. 
In susceptible isolates, the continuation phase 
consists of an additional 4 months with isonia-
zid and rifampicin [9]. However, isoniazid and 
rifampicin are the TB-MDT that experiences re-
sistant frequently.
The resistance of TB-MDT arises through 
several mechanisms [10] (as shown in Fig. 15.5), 
including:
1. The inability of TB-MDT to penetrate into 
M. tuberculosis’ wall cells by reason of its rich 
lipopolysaccharide and mannose.
2. The anaerobic conditions in the site of 
infection enable M. tuberculosis to become 
dormant. The TB-MDT, especially isoniazid, 
is ineffective in dormant conditions.
3. Alteration of enzymes that produced by 
M.tb. These enzymes prevent the conversion 
of prodrugs into active drugs. Isoniazid 
inhibits the synthesis of mycolic acids, which 
are essential components of mycobacterial 
cell walls. Isoniazid is a prodrug that is 
activated by KatG, the mycobacterial 
catalase-peroxidase. The activated form of 
isoniazid forms a covalent complex with 
an acyl carrier protein (AcpM) and KasA, 
a beta-ketoacyl carrier protein synthetase, 
which blocks mycolic acid synthesis. 
Resistance to isoniazid is associated with 
mutations resulting in overexpression of 
FIGURE 15.5 Mechanism of TB-MDT resistance [10].
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inhA, which encodes an NADH-dependent 
acyl carrier protein reductase; mutation, 
or deletion of the katG gene; promoter 
mutations resulting in overexpression of 
ahpC, a gene involved in the protection of 
the cell from oxidative stress; and mutations 
in kasA. Overproducers of inhA express 
low-level isoniazid resistance and cross-
resistance to ethionamide. KatG mutants 
express high-level isoniazid resistance and 
also pyrazinamide resistance.
4. Alteration of target protein structures. This 
prevents drug recognition (rifampicin, 
ethambutol, fluoroquinolones, macrolides).
5. Drug exported from the cell before reaching 
the sites of infection (isoniazid, ethambutol, 
streptomycin).
6. Mutation in DNA repair gene that leads the 
multidrug resistance (MDR)-TB.
Those all aforementioned mechanisms re-
duce the efficacy of TB-MDT.
3 Nanoparticle and its use to conquer 
tuberculosis infection
Nanotechnology is an innovative use of the 
latest technological developments or nanopar-
ticle sized. Nowadays, it has a major impact 
for health and therapeutic development. The 
nanoparticle now is known as a drug delivery 
system, thus it enhances the drug efficacies [14].
In the process of diagnosis, nanotechnology 
may play a role in the diagnostic kit. For ex-
ample in India, The aid of TB diagnosis created 
diagnostic kits in an optical biosensor for rapid 
detection of M.tb bacilli [14,15].
In the TB treatment, nanotechnology has a 
huge improvement in pharmacology, especially 
in the delivery system. The TB-MDT is able to 
reach the site of infection and impact to the func-
tion of macrophage and other phagocyte cells. 
Nanoparticle gives advantages such as combin-
ing MDT into one form, reducing the frequency 
of drugs, increasing the therapeutic index of 
anti-TB, increasing the solubility of hydropho-
bic agents capability, and reducing the admin-
istration of higher doses [16]. As drug delivery, 
nanoparticles also give other advantages such 
as, improve drug stability, improve the ability 
of carrier molecules, and the feasibility of incor-
poration of both hydrophilic and hydrophobic 
substances. Reviewing these carriers can also be 
designed to enable controlled (sustained) drug 
release from the matrix [16].
Nanoparticles as a therapeutic include; na-
noemulsions, nanosuspensions, niosomes, 
polymeric micelles, and other self-assembled 
structures, are roommates antituberculosis drug 
nanocarriers, and polymeric and nonpolymeric 
nanoparticles. Nanoparticles can penetrate the 
intestinal permeability barrier directly through 
the transcellular or paracellular pathways into 
the circulation. This work makes drugs more 
and more effective. Nanosuspensions are a po-
tential and promising new anti-TB drug formu-
lations for intravenous way. Nanoparticles are 
able to achieve the higher stability and ability of 
the drugs, the feasibility of incorporating both 
hydrophobic and hydrophilic substances, and 
the feasibility of any administration routes such 
as parenteral, oral, and inhalation [15].
Nanotechnology increases the bioavailabil-
ity of drugs as a result of a special absorption 
such as the absorption mechanism of endocyto-
sis. The nanoparticles are also able to remain in 
the blood for a longer period of time and in con-
trolled release manner into the target tissue. The 
self-control system of release of the drug helps 
reduce fluctuations in plasma and minimize 
side effects of the drug. In the case of TB adverse 
effects of tuberculosis drugs became one of the 
causes in poor compliance [17].
Nowadays, nanoparticle also develops in or-
der to diminish the number of MDR-TB cases. 
There is a strong urge to develop novel ways 
of delivering the therapeutic compounds to the 
specific target of making the drug more effective 
[14].
 3 Nanoparticle and its use to conquer tuberculosis infection 259
 
Currently, the basic mechanism of controlled 
drug release was established and most drug de-
livery formulations were oral and transdermal 
administration. The effectiveness and stability 
were low in these drug systems. The effective-
ness and stability of the drug will affect drug ac-
tion and its effect on the patient’s body. The drug 
is incorporated into the nanoparticle that eas-
ily diffused through biological membranes and 
cells take up. These particles for the efficiency in 
drug delivery to the site of action. Nanotechnol-
ogy improves the performance of the effective-
ness of the drug, in patients taking the drug lon-
ger, and cost-effectiveness. Nanotechnology can 
produce biodegradable, biocompatible poly-
mers, stimulate, and targeted by following the 
intended target organs, such as liposomes deliv-
er responsive, nanofabricated materials (fuller-
enes, carbon nanotubes, silicon, silica), metals 
(gold, silver, iron, platinum, quantum dots), and 
polymers (micelles, dendrimers). Nanoparticles 
shape assortment such as spherical, rods, wires, 
discs, hemispherical, and ellipsoidal [17].
The size of the nanoparticles that less than 
submicron (<1 µm) colloidal particles are used 
as drug delivery vehicles. For therapeutic pur-
poses, drugs can be covalently embedded to 
the particle surface or can be incorporated in 
the matrix of the particle. Nanoparticles com-
prise biocompatible and biodegradable mate-
rials such as polymers, which can be natural 
(e.g., gelatin and albumin), synthetic (e.g., poly-
lactides and polyalkylcyanoacrylates), or solid 
lipids. Nanoparticles have a higher efficiency 
of the cells compared to the molecules in the 
case of a delivery system. Nanoparticle deliv-
ery system has capabilities that are more spe-
cific and faster. These carriers that are adapted 
to enable controlled, slow, and persistent drug 
release from the matrix [18]. The nanoparticle 
expresses in the gene and able to trace into the 
DNA complexes track (in vivo), this advantage 
is important in simultaneously dosage adminis-
tration and determination. In this determination 
system, the nanoparticle has a high sensitivity 
to measure the level of gene expression (in vivo 
imaging) and is also able to target the specific/
diseased cell types [14].
Nanoscience is a new perspective in making 
early detection, prevention, diagnosis, and treat-
ment in TB became easier and more effective. 
This is because nanoscience has the potential 
to empower local responses to specific targets 
and other benefits to save costs. Nanoparticle-
based gene therapy and drug delivery hold a 
great promise for the sound management of dis-
eases in terms of improved drug bioavailability 
and reduced dosing frequency, though it is ex-
tremely important to investigate the toxic effects 
nanoparticles according to chemistry, size, and 
other physical properties [14].
Future holds up in designing of drug-delivery 
systems or formulations roommates can resolve 
all the limitations of tuberculosis drug therapy 
and making them affordable to all patients. Sev-
eral antitubercular drugs encapsulated in natu-
ral or synthetic carrier-based controlled release 
formulations have been explored and nanopar-
ticles appeared to be the best in terms of thera-
peutic efficacy [14].
Developing research related to vector-based 
delivery systems could combine roommates col-
loidal carriers such as large payloads of drug 
with the active targeting to improve the effec-
tiveness and efficiency of drug action based on 
the nanoparticle-based formulations. Under-
standing the fate of nanocarriers and their poly-
meric constituents along with the elimination of 
any residual organic solvents is a must for deal-
ing with any toxicological issues associated with 
these nanoformulations [14].
Nanoparticle delivery system is a promis-
ing key for the media but it is also against drug-
susceptible tuberculosis and drug resistance. 
Nanoparticles are also useful for reducing the 
burden on the patient’s dose but have the same 
benefits, but simultaneously. Nanotechnology 
still has a lot of homework for future challenges 
especially for TB. Lots of health gaps need to 
be filled along with global sustained efforts to 
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overcome TB infection, in order to reach the site of 
infection in the secondary lymphoid organs [14].
Increasing incidence of multidrug-resistant 
strains make research related to ways of deliv-
ering the therapeutic compounds to the specific 
target of growing. Many delivery systems, such 
as nanoemulsions, nanosuspensions, polymeric 
and nonpolymeric particles, liposomes, nio-
somes, and dendrimers, have been developed in 
the past, overcoming many of the shortcomings 
of the delivery of conventional drugs [14].
4 Function nanoparticle for overcoming 
resistance tuberculosis treatment
TB drug resistance is the inability of the exist-
ing TB drugs to phagocyte mycobacterium that 
exists in the patient’s body, due to the growing 
strength of Mycobacterium tuberculosis that is in-
side the patient’s body TB [19].
Mycobacterium tuberculosis is one of the most 
infection disease which successful human 
pathogens, due to its ability to carry a primary 
infection to a state of dormancy (latents), per-
sisting in the body even in immune-competent 
people. In this regard, it is important to mention 
that there are two billion people infected world-
wide by M.tb, and only nine million people 
develop into TB clinical diseases, for example: 
from 100 people whom were exposed with M.tb, 
only 2 persons grow into clinical TB infection, 
this phenomenon is due to immune response. 
TB is usually a lung disease, due to the fact that 
these organs are the gateway and provide opti-
mal conditions for the infected of this disease. 
The primary infection begins with the inhala-
tion of the particles of Mycobacterium tuberculo-
sis. Approximately 10% of this invasion due to 
respiratory tract that are in alveoli and bron-
chioles, where the bacteria is recognized and 
phagocytozed by alveolar macrophages (AMs) 
or dendritic cells (DCs). Macrophages exposed 
to Mycobacterium tuberculosis secrete pro-inflam-
matory cytokines (IL-1, TNF-α, and IL-6) that 
will contribute to the subsequent formation of 
focal granulomatous lesions, a process that takes 
2-3 weeks, and which generally leads to the con-
tainment of the pathogen [8].
Pharmacotherapy of tuberculosis therapeutic 
regimen is recommended by the WHO for sus-
ceptible pulmonary TB rifampicin, isoniazid, 
pyrazinamide, ethambutol, and streptomycin. 
The therapy in tuberculosis consists of a short-
term treatment of 6 months (divided into two 
stages), intensive phage and continue phage 
[8,10,20]. Drug chemical structures could be 
seen in Fig. 15.6.
Tuberculosis drug resistance or multidrug re-
sistant tuberculosis (MDR TB) is a condition in 
which a patient is resistant to first-line TB treat-
ment. The first-line drug is a list of the first drug 
given to patients with TB occurrence. This is be-
cause of the resistance of patients who dropped 
out treatment or in patients who are infected 
with Mycobacterium tuberculosis for the ump-
teenth time. The inability of antituberculosis 
(anti-TB) has become one of the causes in which 
a patient MDR-TB or now known by extra-drug 
resistant tuberculosis (XDR-TB) must increase 
the dosage of antituberculosis drugs and make 
the treatment of TB becomes longer. The efficacy 
of antiinfective drugs is not only dependent on 
the pathogens related to MIC, but also on the ex-
posure of the drug in the patient [21].
Combination of nanomaterials with the un-
derstanding of differentiation of biological pro-
cesses, nanotechnology could ameliorate and 
trigger the usage of brand new drug/antigen in 
delivery systems. Based on evidence nanomate-
rials have a result better than liposomes, there 
about stabilization and drug loading capacity. 
The differentiation of nanoformulations, like lip-
id-based and (branched) polymeric ones, is be-
ing explored to deliver different types of drugs. 
In recent years, many efforts have been directed 
to the encapsulation of anti-TB drugs within 
nanoparticles [8].
Low compliance, the main cause that makes 
the incidence of drug resistance to anti-TB 
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against Mycobacterium tuberculosis, is increasing. 
Now it has become clear that pharmacokinetic 
variability is much more likely to be the driv-
ing force of drug resistance. The development 
of pharmacokinetic required in the case of an-
tituberculosis drug resistance (anti-TB). If the 
existing infection with TB addressed adequate-
ly, then the bacteria will not occur and can be 
treated. However, in the case of anti-TB drugs, a 
therapeutic range or the target has not been es-
tablished.[21].
Nanoparticles are believed to increase the sig-
nificance of the treatment of TB from diagnosis, 
treatment, and prevention. Nanotechnology is 
one of the functions that improve nanomedicine. 
Due to reviews, their size, shape, and morpholo-
gy (less than 100 nm in one aspect) nanoparticles 
exhibit different properties of the same material 
when they are in bulk size. New diagnostics and 
therapeutics for application in organ systems 
have been developed due to the unique proper-
ties of nanopharmaceuticals [22].
Nanomedicine approaches are being used as 
effective carriers of drugs to different parts of 
the body that were previously difficult to access. 
Nanomedicine approach in anti TB enhances the 
efficacy of the drugs. It may possible to the target 
nanoparticles to specific organs by modifying 
FIGURE 15.6 Pharmacotherapy of tuberculosis [10].
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the elemental composition, size, shape, charge, 
and surface modification or functionalization 
[22].
That brings us to the second reason why we 
need new anti-TB drugs. Drug resistance has 
emerged as a phantom from the dark, threat-
ening today every corner of the world. Often 
RIF-resistance correlates to the MDR category 
(resistant to INH and RIF). XDR is an MDR M. 
tuberculosis strains resistant to any fluoroquino-
lone also and at least one injectable agent. The 
prognosis is less favorable for harboring XDR-
bacilli patients compared to patients with MDR, 
with a five times higher risk of death, therefore 
the XDR patients need to be hospitalized or re-
quires longer treatment times. However, it has 
been shown that within an aggressive treatment, 
XDR-TB patients have been successfully cured 
by 60%. The treatment of M/XDR-TB usually 
takes more than 2 years, and requires the use of 
more toxic, less effective, and more expensive 
drugs [15].
Pulmonary tuberculosis is the most ubiq-
uitous form of the disease, and the respiratory 
path represents the means of delivering a unique 
ATD’s directly to the lungs. The reduction of tox-
icity and accomplishing higher systemic drug 
concentration at the chief site of infection are the 
promising advantages of the direct delivery of 
the drug to the lungs. Inhalable nanoparticles 
possess an enhanced ability of mucosal adher-
ence, particle delivery, and net drug delivery to 
the lungs [23].
Anti-TB drug carriers are classified: synthetic 
or natural origin. They allow the flexibility of 
selecting the route of drug delivery, Depending 
on the drug formulation. Not only the smaller 
size but also the ability of higher drug encapsu-
lation and enhancement of the orally adminis-
tered-drug bioavailability is the key difference 
between the nanoparticles and microparticles. 
poly-dl-lactide-co-glycolide (PLG)-A nanopar-
ticles are commonly used in preparation for 
emulsification or evaporation [15].
Nanomedicine approach significantly pro-
longed provided a mean residence time, and 
elimination half-life of the drugs in comparison 
to the conventional orally administered formu-
lations and resulted in an enhanced relative bio-
availability for the nanoparticle-preparations 
(rifampicin, pyrazinamide, and isoniazid). The 
nebulization of the nano-encapsulated drug led 
to an absence of Mycobacterium tuberculosis in the 
lungs [17].
Drug resistance tuberculosis is an important 
health issue in progress made in TB care and con-
trol programs worldwide. Drug resistance arises 
due to pathogen inappropriate use of medicines 
in the treatment of drug-susceptible tuberculosis 
patients. This improper use may be due to the 
administration of improper treatment regimens 
and the failure of noncompliance of the patients 
to complete the course of therapy [17].
The treatment of tuberculosis has become 
a challenge for the physicians because of the 
emerging threat of drug-resistant strains of 
the pathogen. The M. tuberculosis responsible for 
the disease can overcome the cellular defense 
mechanisms, infecting the cells and turning 
them into reservoirs. The drawbacks of conven-
tional tuberculosis drug formulation are the in-
ability to kill the intracellular pathogens because 
of reviewing their limited bioavailability and 
limited penetration power in the targeted patho-
gens to produce a therapeutic effect [17].
Nanomedicine has the potential to challenge 
such limitations and improve the therapeutic ef-
ficacy of such drugs. Nanovesicles formulation 
of gentamicin, vancomycin amikacin, kanamy-
cin, streptomycin, present enhanced in vitro and 
in vivo efficacy. Reviewing these formulations 
successfully reduced the viable bacteria counts 
of M. tuberculosis. However, in some cases, the 
pulmonary availability of the drugs was small 
or absent roommates can overcome by the de-
velopment of localized particles targeted for de-
livery by inhalation or by targeting the pulmo-
nary area [17].
 5 Nanoparticle for diagnose tuberculosis 263
 
5 Nanoparticle for diagnose tuberculosis
Diagnose tuberculosis with detection of my-
cobacterium DNA in clinical samples using 
nanoparticles has been developed, and it is a 
great futuristic vision. Nanocrystalline silicon 
photodetector with suitable software can detect-
ing tuberculosis for diagnose tuberculosis and it 
could be to lessen the human error in diagnose 
tuberculosis. Recently, a convenient and low-
cost biosensing platform was presented to detect 
Mycobacterium tuberculosis [24].
Exploated of scanobased, fluoremetric, colori-
metric, surface-enhanced Raman scattering and 
electrochemical methodologies as a ultrasensi-
tive techniques can developed to detect gold 
nanoparticles in clinical sputum samples, which 
that engineered with thiol-modified oligonucle-
otides to make the detection efficient, simplified, 
and relatively cheaper. Mycobacterium tuberculo-
sis can be easily differentiated from other mem-
bers of Mycobacterium species with the help of 
these nanoparticles. Fluorescent semiconduc-
tor quantum dots and magnetic beads are also 
used to detect DNA of Mycobacterium species 
without prior PCR. Even the probe consisting of 
superparamagnetic ironoxide nanoparticles has 
been designed and this probe is specific for diag-
nosing the extrapulmonary TB [24].
Nanoparticles are versatile and diverse with 
respect to their properties and structural, which 
enables them to be used for clinical diagnosis 
and effective drug delivery purpose in a unique 
and more reliable manner. Owing to their wide 
range of distribution manner and functional 
modes, nanoparticles can be used for multiple 
applications. The main reason behind this is the 
excellent geometric control of structures by ar-
resting their formation during different stages of 
their synthesis. Better and more effective disease 
treatment protocols can be achieved with the 
use of systems like programmable nanorobots 
that can be employed for site-specific drug de-
livery [24].
Dendrimers has a layer, outer core on den-
drimers there has hydrophilic characteristic and 
on an inside core on dendrimers has hydropho-
bic characteristic, so possible to deliver material 
component (as shown in Figs. 15.6 and 15.7). 
This arrangement forms the basic formulation 
FIGURE 15.7 Different nanotechnology-based approaches [8].
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for dendrimers in drug delivery systems. Myco-
bacterium is a Gram-negative bacterium. Its cell-
wall composition (a rich layer of mycolic acid) 
renders it difficult for potential anti-TB medici-
nal preparations to enter into the infected cells. 
With the use of dendrimers, the conformation of 
the carried medicinal formulation is biochemi-
cally altered in a way that favors its entry into 
the specific target cells [24].
Nanoparticles have also been explored for the 
coencapsulation of tuberculosis drugs. Respira-
tory delivery developed because nanocarriers 
loaded with RIF, INH, and PYR. Data demon-
strated that the inhalable nanotechnological 
platform allowed improving the pharmacother-
apy regimen in Mycobacterium tuberculosis infect-
ed. Nanoparticles were investigated to encapsu-
late these tuberculosis drugs. Polymeric micelles 
(PMs) have become well-investigated nanove-
hicles. They are composed by amphiphilic bio-
compatible polymers that can self-assemble into 
nanostructures when the polymers concentra-
tion is above their critical micellar concentra-
tion. The pharmacotherapy of tuberculosis: this 
strategy has not been explored as LPs and NPs. 
The selection of the biomaterials and the phar-
maceutical additives allowed developing differ-
ent dosage forms (Figs. 15.8 and 15.9) [8].
Nanosuspension can make more efficient 
absorption and better biodistribution of drug 
molecules. During the formulation of a nano-
suspension, the crystalline particles of the drug 
are converted into amorphous form. The con-
version to amorphous forms can be achieved us-
ing X-ray diffraction. Various parameters such 
as particle size, charge distribution, and drug 
dissolution celerity also can be more effectively 
and easily monitored as well as suitably modi-
fied to suit a particular kind of drug delivery 
mechanism. Nanoemulsions represent a stable 
thermodynamic mixture. The use of rifampicin-
based nanoemulsions for TB pharmacotherapy: 
they have elaborated the critical design features 
such as viscosity, solubility, and chemical inter-
action ability for nanoemulsion design to be-
come optimized drug delivery vehicles. It has 
been successfully used for the killing of Myco-
bacterium tuberculosis germs at low dosage, and 
there is hardly any risk of toxicity or side effects 
(Fig. 15.10) [24].
There is a significant improvement from 
anti-TB drugs with nanoparticle than free anti-
TB drugs. Relativity, bioavailability and mean 
residence time of encapsulated drugs more sig-
nificant. Five aerosolized doses of PLG nanopar-
ticles coencapsulating rifampicin, isoniazid, and 
pyrazinamide revealed undetectable cfu in the 
lungs. Comparison with microparticles: first, 
the decrease of lung cfu was better, and second, 
coadministration of three anti-TB drug encap-
sulations was possible in nanoparticles delivery 
system. As detection of Mycobacterium tubercu-
losis nanotechnology more expendable and ef-
ficient, especially high sensitivity so diagnose 
of tuberculosis more effective and efficient be-
cause nanoparticles can be tagged with suitable 
ligands and can be functionalized with various 
lectins to make more effective PLG nanoparticle 
uptake [15].
FIGURE 15.8 Dendrimers based nanotechnological 
treatment [8].
 
FIGURE 15.9 Nanomedicine in tuberculosis [8].
FIGURE 15.10 Mechanism of both natural and synthetic drug carriers by nanoparticle [14].
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